drugset / Trial / NCT06568458

A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

NCT06568458

Phase 1 Completed 71 enrolled Bristol-Myers Squibb
Non-randomizedSequentialOpen-labelTreatment

Summary

The Purpose of the Study is to Assess the Drug Interaction and Bioavailability of BMS-986278 in Tablet Formulations and the Effect that Food has on BMS-986278 in Tablet Formulation in Healthy Participants

Timeline

Start
2024-09-19
Primary completion
2025-02-27
Completion
2025-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Admilparant Small molecule Oral
Subject Nintedanib Small molecule

Indications

No indication recorded.